Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, studies immunotherapy and immunopathology in cancer and infectious diseases. His current research interests include investigating and understanding the mechanisms underlying IR-induced extrinsic resistance as well as testing newly developed personalized immunotherapies to overcome these resistance mechanisms for improved and long-lasting tumor control.
After completing his clinical training in pathology at Washington University in St. Louis (1998), Dr. Fu organized his own team to focus his research on understanding the role of the lymphoid microenvironment in cellular and humoral immune responses using various TNF superfamily members such as the LIGHT/lymphotoxin pathway.
His team has published more than 50 papers relating to the mechanistic understanding of autoimmunity and immunity against pathogens and tumor in top journals (e.g., Science, Nature, Nature Immunology, Nature Medicine, Cancer Cell, Immunity, Journal of Experimental Medicine, and Journal of Clinical Investigation). He has directed clinical, translational, and preclinical studies in immunology––tumor immunology in particular––for more than 15 years. Recently, his team has been developing novel immunotherapeutic molecules, antibodies and armed antibodies by protein engineering. They have established mouse tumor models expressing various oncogenic receptors to mimic clinical tumors and have made significant progress in understanding how traditional cancer therapies both rely on and impact the immune system.
- Medical School
- Shanghai Medical University (1983), Medicine
- Graduate School
- University of Miami (1990), Immunology
- IR-mediated immunity and tumor regression
- Lymphotoxin biology and gut Immunity
- Next generation antibody-based molecules
- Tumor immunology
- Targeting IFNa to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance.
- Liang Y, Tang H, Guo J, Qiu X, Yang Z, Ren Z, Sun Z, Bian Y, Xu L, Xu H, Shen J, Han Y, Dong H, Peng H, Fu YX Nat Commun 2018 11 9 1 4586
- LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
- Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC Nature 2018 Oct 562 7728 605-609
- Non-canonical NF-?B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy.
- Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, Arina A, Weichselbaum RR, Fu YX Immunity 2018 Sep 49 3 490-503.e4
- CTLA-4 limits anti-CD20-mediated tumor regression.
- Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu YX Clin. Cancer Res. 2016 Jun
- PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment.
- Ren Z, Peng H, Fu YX Cancer Discov 2016 May 6 5 477-8
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
- Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu YX Cancer Cell 2016 Mar 29 3 285-96
- Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
- Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX J. Clin. Invest. 2014 Feb 124 2 687-95
- Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
- Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX Cancer Cell 2014 Jan 25 1 37-48
- Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing.
- Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, Fu YX J. Immunol. 2013 Jun 190 11 5874-81
- Effective anti-neu initiated anti-tumor responses require the complex role of CD4+ T cells.
- Mortenson E, Park S, Zhujun J, Wang S, Fu YX Clin. Cancer Res. 2013 Jan